Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.coph.2020.06.001 http://scihub22266oqcxt.onion/10.1016/j.coph.2020.06.001 32682281!8061532!32682281     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32682281&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Curr+Opin+Pharmacol 2020 ; 54 (?): 11-17 Nephropedia Template TP {{tp|p=32682281|t=2020. Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance |pdf=|usr=}}{{32682281}} gab.com Text Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance JO: Curr Opin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32682281 #FOAvip Robust clinical data indicate that inhibitors of the sodium/glucose cotransporter 2 (SGLT2) dramatically improve clinical outcomes in diabetes, especially heart failure and progression of kidney disease. Factors that may contribute to these findings include: 1) improved glycemic control, 2) diuresis and reduced extracellular fluid volume, 3) reduced serum uric acid levels, 3) direct myocardial effects, 4) reduction in proteinuria and preservation of kidney function, and 5) correction of diabetic magnesium deficiency. Understanding the mechanisms by which SGLT2 inhibitors improve cardiovascular outcomes has the potential to improve clinical management not only of diabetes, but also of other cardiovascular disorders such as heart failure and chronic kidney disease. Twit Text FOAVip Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance ????Curr Opin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32682281 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32682281 #FOAvip English Wikipedia <ref>{{Cite pmid|32682281}}</ref> Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance #MMPMID32682281 Ray EC Curr Opin Pharmacol 2020[Oct]; 54 (?): 11-17 PMID32682281show ga Robust clinical data indicate that inhibitors of the sodium/glucose cotransporter 2 (SGLT2) dramatically improve clinical outcomes in diabetes, especially heart failure and progression of kidney disease. Factors that may contribute to these findings include: 1) improved glycemic control, 2) diuresis and reduced extracellular fluid volume, 3) reduced serum uric acid levels, 3) direct myocardial effects, 4) reduction in proteinuria and preservation of kidney function, and 5) correction of diabetic magnesium deficiency. Understanding the mechanisms by which SGLT2 inhibitors improve cardiovascular outcomes has the potential to improve clinical management not only of diabetes, but also of other cardiovascular disorders such as heart failure and chronic kidney disease. |Animals[MESH] |Cardiovascular Diseases/*prevention & control[MESH] |Diabetes Complications/*prevention & control[MESH] |Heart/drug effects[MESH] |Humans[MESH] |Kidney Diseases/*prevention & control[MESH] |Kidney/drug effects[MESH] |Magnesium/blood[MESH] |Protective Agents/*therapeutic use[MESH] |Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use[MESH]Evolving understanding of cardiovascular protection by SGLT2 inhibitor(epmc).pdf DeepDyve Pubget Overpricing